ALKS on Nasdaq
Alkermes
Irish-domiciled healthcare company
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall.3 From Wikipedia, CC BY-SA 4.0
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with PHIBRO ANIMAL HEALTH CORP, PTC Therapeutics or Indivior, or pick any stock.
- TickerALKS on Nasdaq1
- Industrypharmaceutical industry1
- HeadquartersDublin1
- Websitewww.alkermes.com
- Business addressConnaught House, 1 Burlington Road, Dublin 4, L2 000004
- Filer categoryLarge accelerated filer4
See how the biggest companies compare on our leaderboards
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies (EDT), the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio.3
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Vivitrol brought in 32% of the revenue Alkermes broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Vivitrol | $400.4M | $457.3M | $467.9M |
| Aristada And Aristada Initio | $327.7M | $346.2M | $370.0M |
| Lybalvi | $191.9M | $280.0M | $346.7M |
| Royalty | $600.9M | $354.7M | $245.3M |
| Manufacturing Revenue | $142.5M | $119.4M | $46.0M |
Regions
United States brought in 93% of the revenue Alkermes broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $1.5B | $1.4B | $1.4B |
| Foreign Country Excluding Specified Country | $170.3M | $146.2M | $102.4M |
| I E | $1.2M | $1.3M | $754.0K |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue13¢$196.5M
- Research and development21¢$324.0M
- Selling, general and admin46¢$701.5M
- Income tax3¢$49.8M
- Profit16¢$241.7M
Out of $1.5B in revenue.6
Where each dollar of operating cash went, fiscal 2025
- Capital spending8¢$40.4M
- Kept or used elsewhere92¢$480.3M
Out of $520.8M of cash from operations.6
Financial statements
Every line of the income statement in the latest annual report, as filed.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total revenues | $1.5B | $1.6B | $1.7B |
| Cost of goods manufactured and sold (exclusive of amortization of acquired intangible assets shown below) | $196.5M | $245.3M | $253.0M |
| Research and development | $324.0M | $245.3M | $270.8M |
| Selling, general and administrative | $701.5M | $645.2M | $689.8M |
| Amortization of acquired intangible assets | $1.1M | $35.7M | |
| Total expenses | $1.2B | $1.1B | $1.2B |
| OPERATING INCOME FROM CONTINUING OPERATIONS | $254.0M | $420.6M | $414.1M |
| Interest income | $45.3M | $42.5M | $30.9M |
| Interest expense | -$12.3M | -$22.6M | -$23.0M |
| Other income (expense), net | $4.5M | $3.2M | -$425.0K |
| Total other income, net | $37.5M | $23.1M | $7.4M |
| INCOME BEFORE INCOME TAXES | $291.4M | $443.8M | $421.5M |
| INCOME TAX PROVISION (BENEFIT) | $49.8M | $71.6M | -$97.6M |
| NET INCOME FROM CONTINUING OPERATIONS | $241.7M | $372.1M | $519.2M |
| LOSS FROM DISCONTINUED OPERATIONS, NET OF TAX | -$5.1M | -$163.4M | |
| NET INCOME | $241.7M | $367.1M | $355.8M |
| Earnings per ordinary share from continuing operations - basic | $1 | $2 | $3 |
| Loss per ordinary share from discontinued operations - basic | -$0 | -$1 | |
| Earnings per ordinary share - basic | $1.47 | $2.22 | $2.14 |
| Earnings per ordinary share from continuing operations - diluted | $1 | $2 | $3 |
| Loss per ordinary share from discontinued operations - diluted | -$0 | -$1 | |
| Earnings per ordinary share - diluted | $1.43 | $2.17 | $2.10 |
| Basic | 164.7M shares | 165.4M shares | 166.2M shares |
| Diluted | 168.7M shares | 169.2M shares | 169.7M shares |
| Holding (loss) gain, net of a tax (benefit) provision of $(55), $292, and $1,195, respectively | -$133.0K | $1.1M | $7.8M |
| COMPREHENSIVE INCOME | $241.5M | $368.2M | $363.5M |
| Tax provision (benefit) | -$55.0K | $292.0K | $1.2M |
Every line of the balance sheet in the latest annual report, as filed.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $388.6M | $291.1M | $457.5M |
| Restricted cash | $731.2M | ||
| Investmentsshort-term | $199.6M | $460.5M | |
| Receivables, net | $334.0M | $384.5M | |
| Inventory | $196.6M | $182.9M | |
| Prepaid expenses and other current assets | $79.1M | $91.3M | |
| Contract assets | $0 | $5.0M | |
| Total current assets | $1.9B | $1.4B | |
| PROPERTY, PLANT AND EQUIPMENT, NET | $221.7M | $227.6M | |
| INVESTMENTSLONG-TERM | $145.0K | $73.1M | |
| RIGHT-OF-USE ASSETS | $77.2M | $84.2M | |
| INTANGIBLE ASSETS, NET AND GOODWILL | $83.8M | $83.9M | |
| DEFERRED TAX ASSETS | $125.8M | $154.8M | |
| OTHER ASSETS | $49.1M | $16.5M | |
| TOTAL ASSETS | $2.5B | $2.1B | |
| Accounts payable and accrued expenses | $289.6M | $185.3M | |
| Accrued sales discounts, allowances and reserves | $247.1M | $272.5M | |
| Operating lease liabilitiesshort-term | $6.7M | $6.2M | |
| Contract liabilitiesshort-term | $0 | $1.2M | |
| Total current liabilities | $543.4M | $465.2M | |
| OPERATING LEASE LIABILITIESLONG-TERM | $63.3M | $69.4M | |
| OTHER LONG-TERM LIABILITIES | $61.0M | $56.0M | |
| Total liabilities | $667.7M | $590.6M | |
| Ordinary shares, par value, $0.01 per share; 450,000,000 shares authorized; 181,011,166 and 176,670,785 shares issued; and 165,607,028 and 162,176,994 shares outstanding at December 31, 2025 and 2024, respectively | $1.8M | $1.8M | |
| Treasury shares, at cost (15,404,138 and 14,493,791 shares at December 31, 2025 and 2024, respectively) | -$450.3M | -$419.3M | |
| Additional paid-in capital | $3.0B | $2.9B | |
| Accumulated other comprehensive loss | -$2.1M | -$2.0M | |
| Accumulated deficit | -$734.8M | -$976.5M | |
| Total shareholders equity | $1.8B | $1.5B | $1.2B |
| TOTAL LIABILITIES AND SHAREHOLDERS EQUITY | $2.5B | $2.1B | |
| Preferred stock shares, par value (in dollars per share) | $0.01 | $0.01 | |
| Preferred stock shares, authorized | 50.0M shares | 50.0M shares | |
| Preferred stock shares, issued | 0 shares | 0 shares | |
| Preferred stock shares, outstanding | 0 shares | 0 shares | |
| Ordinary shares, par value (in dollars per share) | $0.01 | $0.01 | |
| Ordinary shares, shares authorized | 450.0M shares | 450.0M shares | |
| Ordinary shares, shares issued | 181.0M shares | 176.7M shares | |
| Ordinary shares, shares outstanding | 165.6M shares | 162.2M shares | |
| Treasury shares | 15.4M shares | 14.5M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net income | $241.7M | $367.1M | $355.8M |
| Depreciation and amortization | $27.2M | $28.5M | $74.9M |
| Share-based compensation expense | $98.7M | $96.6M | $100.9M |
| Deferred income taxes | $28.8M | $40.5M | -$99.9M |
| Other non-cash charges | $5.3M | $4.5M | $6.3M |
| Receivables | $50.5M | -$52.1M | -$44.5M |
| Contract assets | $5.0M | -$4.3M | $8.2M |
| Inventory | -$14.1M | $3.1M | -$2.7M |
| Prepaid expenses and other assets | $852.0K | $2.3M | -$34.8M |
| Right-of-use assets | $7.5M | $7.2M | $15.4M |
| Accounts payable and accrued expenses | $100.9M | -$58.0M | $23.0M |
| Accrued sales discounts, allowances and reserves | -$25.3M | $8.8M | $11.5M |
| Contract liabilities | -$1.2M | -$3.5M | -$5.9M |
| Operating lease liabilities | -$10.3M | -$10.1M | -$16.1M |
| Other long-term liabilities | $5.3M | $8.4M | $9.3M |
| Cash flows provided by operating activities | $520.8M | $439.1M | $401.4M |
| Additions of property, plant and equipment | -$40.4M | -$33.5M | -$48.0M |
| Proceeds from the sale of property, plant and equipment | $1.1M | $461.0K | $354.0K |
| Return of Fountain Healthcare Partners II, L.P. investment | $43.0K | ||
| Proceeds from the sale of the Athlone Facility | $1.7M | $97.9M | |
| Purchases of investments | -$364.4M | -$486.5M | -$254.5M |
| Sales and maturities of investments | $697.5M | $310.3M | $355.5M |
| Cash flows provided by (used in) investing activities | $295.5M | -$111.3M | $53.4M |
| Cash transferred to Mural Oncology plc at separation | -$275.0M | ||
| Proceeds from the issuance of ordinary shares under share-based compensation arrangements | $43.4M | $27.6M | $16.8M |
| Employee taxes paid related to net share settlement of equity awards | -$31.0M | -$29.6M | -$28.5M |
| Payment for the repurchase of ordinary shares | -$200.3M | ||
| Prepayment of long-term debt | -$289.5M | ||
| Principal payments of long-term debt | -$2.2M | -$3.0M | |
| Cash flows provided by (used in) financing activities | $12.4M | -$494.1M | -$289.7M |
| NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | $828.6M | -$166.3M | $165.0M |
| Cash paid for interest | $23.0M | $22.7M | |
| Cash paid for taxes | $5.2M | $2.6M | $44.2M |
| Purchased capital expenditures included in accounts payable and accrued expenses | $3.1M | $2.3M | $2.6M |
Products and brands
Alkermes has five proprietary commercial drug products approved for the treatment of narcolepsy, schizophrenia, bipolar I disorder, alcohol dependence and opioid dependence. These include sodium oxybate for extendend release oral suspension (Lumryz) olanzapine and samidorphan (Lybalvi), an atypical antipsychotic and opioid modulator combination intended for the treatment of schizophrenia and bipolar I disorder; aripiprazole lauroxil (Aristada), a long-acting injectable for schizophrenia; and naltrexone for extended-release injectable suspension (Vivitrol) for alcohol and opioid dependence.
Other products utilizing Alkermes' proprietary technologies include: diroximel fumarate (Vumerity) for multiple sclerosis, risperidone (microspheres) long-acting injectable (Risperdal Consta) for schizophrenia and bipolar I disorder, paliperidone palmitate (Invega Sustenna, Invega Trinza and Invega Hafyerain in the U.S., Xeplion, Trevicta and Bynnali in Europe) for schizophrenia.
In October 2023, Alkermes announced its first data related to its orexin 2 receptor (OXR2) agonist, alixorexton, previously known as ALKS 2680. Alixorexton is in development for the treatment of narcolepsy and idiopathic hypersomnia.
In November 2023, Alkermes completed the planned separation of its oncology business into a new company, Mural Oncology, which plans to continue to work on the investigational interleukin-2 (IL-2) drug, nemvaleukin alfa.
Read the full text
In May 2024, Alkermes completed the sale of its Athlone, Ireland facility to Novo.
In April 2025, Alkermes announced the initiation of a phase 2 study of alixorexton for the treatment of idiopathic hypersomnia.
In July 2025, Alkermes announced positive topline results from Vibrance-1, a phase 2 study evaluating alixorexton for the treatment of narcolepsy type 1.
In November 2025, Alkermes agreed to acquire sleep disorder drugmaker Avadel Pharmaceuticals for up to $2.37 billion, which includes $21 per share in cash plus $1.50 per share contingent on expanded approval of Lumryz by the end of 2028. This resulted after a bidding war between Alkermes and Danish pharmaceutical company Lundbeck. Alkermes had originally offered up to $2.1 billion, which included $18.50 per share plus the contingent $1.50. The deal closed in the first quarter of 2026.
In February 2026, CEO Richard Pops announced plans to effective August 2026. His planned replacement is Blair Jackson, Alkermes' current Chief Operating Officer.
Alkermes has multiple orexin 2 receptor agonists in development for the potential treatment of fatigue associated with multiple sclerosis and Parkinson's disease as well as attention-deficit hyperactivity disorder.
From Wikipedia’s article on Alkermes plc, shared under CC BY-SA 4.0.5
Subsidiaries and ownership
Subsidiaries
- Alkermes (United States)
From Wikidata.1
Former names
Recent filings
- Oct 9, 20264 PRIMARY DOCUMENT
- Oct 9, 20264 PRIMARY DOCUMENT
- Oct 2, 2026144
- Oct 2, 20264 PRIMARY DOCUMENT
- Sep 21, 20268-K
- Sep 18, 20263 PRIMARY DOCUMENT
- Sep 16, 20268-K
- Sep 3, 2026144
- Sep 3, 20264 PRIMARY DOCUMENT
- Sep 1, 2026144
- Sep 1, 20264 PRIMARY DOCUMENT
- Aug 17, 2026144
- Aug 17, 20264 PRIMARY DOCUMENT
- Aug 12, 20268-K
- Aug 7, 20264 PRIMARY DOCUMENT
Every filing from the last three years, summarized. The full record is on SEC EDGAR.2
Links
- Websitewww.alkermes.com1
- WikipediaAlkermes plc
- WikidataQ4727688
- SEC EDGARCIK 1520262
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1WikidataAlkermes on Wikidata
- 2SEC EDGARAlkermes filings on SEC EDGAR
- 3WikipediaAlkermes on Wikipedia
- 4SEC EDGARAlkermes filings on SEC EDGAR
- 5
- 6SEC EDGARAlkermes 10-K for fiscal 2025
- 7SEC EDGARAlkermes 10-K for fiscal 2019
- 8SEC EDGARAlkermes 10-K for fiscal 2020
- 9SEC EDGARAlkermes 10-K for fiscal 2021
- 10SEC EDGARAlkermes 10-K for fiscal 2022
- 11SEC EDGARAlkermes 10-Q for fiscal 2026
- 12SEC EDGARAlkermes 10-Q for fiscal 2026
- 13SEC EDGARAlkermes 10-K for fiscal 2019